Ascentage Pharma Group Inc.

Ascentage Pharma Group Inc. focuses on blood cancers including acute myeloid leukemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, chronic myeloid leukemia, and Philadelphia chromosome-positive acute lymphoblastic leukemia. Its clinical work also extends to myelodysplastic syndrome, with attention to both newly diagnosed and relapsed or refractory disease settings.

• Acute myeloid leukemia
• Chronic lymphocytic leukemia and small lymphocytic lymphoma
• Chronic myeloid leukemia
• Philadelphia chromosome-positive acute lymphoblastic leukemia
• Myelodysplastic syndrome

The sponsor’s portfolio includes therapies for both frontline and previously treated haematologic cancers, with a strong concentration on lymphoid malignancies and myeloid neoplasms.